Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Jiangsu Hansoh Pharmaceutical is the lead sponsor of 33 current clinical trials in our China and USA registers. 18 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are HS-10370, Adebrelimab and Carboplatin. The most-studied condition is Non-small Cell Lung Cancer.

ClinicalTrials.gov trials by status

Recruiting1855%
Not yet open1236%
Active, closed39%

Trials by phase

Phase 11648%
Phase 3618%
Phase 1/2618%
Phase 239%
Phase 426%

Clinical trials sponsored by Jiangsu Hansoh Pharmaceutical

33 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118 NCT07033234 · ClinicalTrials.gov ↗ · Psoriasis Drug: HS-20118	Phase 1	Recruiting	2025-05	China
Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma NCT07097935 · ClinicalTrials.gov ↗ · Advanced Clear Cell Renal Cell Carcinoma Drugs: HS-10516, Lenvatinib	Phase 1/2	Recruiting	2025-07	China
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer NCT04951635 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Recruiting	2021-03	China
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118 NCT06846710 · ClinicalTrials.gov ↗ · Psoriasis Drug: HS-20118	Phase 1	Recruiting	2025-05	USA
A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer NCT06147570 · ClinicalTrials.gov ↗ · Nonsmall Cell Lung Cancer	Phase 2	Recruiting	2023-09	China
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors NCT05740956 · ClinicalTrials.gov ↗ · Ovarian Cancer, Breast Cancer, Pancreatic Cancer	Phase 1	Recruiting	2023-06	China
A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. NCT05367700 · ClinicalTrials.gov ↗ · CML, Chronic Phase, CML, Accelerated Phase	Phase 1	Recruiting	2022-04	China
A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC NCT06926413 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 1	Recruiting	2025-02	China
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) NCT05435248 · ClinicalTrials.gov ↗ · Advanced or Metastatic NSCLC	Phase 1/2	Recruiting	2022-03	China
Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors NCT05367778 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drug: HS-10370	Phase 1/2	Recruiting	2022-06	China
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors NCT06769425 · ClinicalTrials.gov ↗ · Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer	Phase 1	Recruiting	2025-05	China
Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria NCT07470762 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Hemoglobinuria	Phase 1/2	Recruiting	2026-02	China
A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy NCT07468851 · ClinicalTrials.gov ↗ · High-risk Non-muscle-invasive Bladder Cancer	Phase 1/2	Recruiting	2026-08	China
A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors NCT05911464 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	2023-03	China
HS-10542 Study in Healthy Participants NCT07040046 · ClinicalTrials.gov ↗ · Healthy Drug: HS-10542	Phase 1	Recruiting	2025-05	China
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors NCT06553339 · ClinicalTrials.gov ↗ · Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma Drug: HS-10516	Phase 1	Recruiting	2024-07	China
A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) NCT06461156 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic NSCLC	Phase 1	Recruiting	2024-06	China
A Study of HS-20094 in Overweight or Obese Participants NCT07057674 · ClinicalTrials.gov ↗ · Overweight or Obesity	Phase 1	Recruiting	2025-04	China
Efficacy and Safety Study of HS-10542 for IgA Nephropathy NCT07474636 · ClinicalTrials.gov ↗ · IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease Drug: HS-10542	Phase 2	Not yet open	2026-03	China
A Phase I Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10506 in Healthy Chinese Adult Participants NCT07535970 · ClinicalTrials.gov ↗ · Healthy Participants	Phase 1	Not yet open	2026-04	China
A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease NCT07555054 · ClinicalTrials.gov ↗ · Chronic Kidney Disease Drugs: HS-10390, Irbesartan	Phase 2	Not yet open	2026-05	China
A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone NCT07156500 · ClinicalTrials.gov ↗ · Type 2 Diabetes	Phase 3	Not yet open	2025-09	China
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors NCT06594874 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Advanced Solid Tumors Drugs: Adebrelimab, Carboplatin, Cisplatin	Phase 1	Not yet open	2024-10	China
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors NCT06963502 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer Drugs: Adebrelimab, Capecitabine, Carboplatin	Phase 1	Not yet open	2025-05	China
A Phase 3 Study of HS-20094 in Patients With T2DM NCT07156539 · ClinicalTrials.gov ↗ · Type 2 Diabetes Drug: Dulaglutide	Phase 3	Not yet open	2025-09	China
A Study to Evaluate the Long-term Safety of HS-10380 in Patients With Schizophrenia NCT07759869 · ClinicalTrials.gov ↗ · SCHIZOPHRENIA 1 (Disorder)	Phase 3	Not yet open	2026-09	China
Phase 1 Study of HS-20152 in Healthy Participants NCT07503015 · ClinicalTrials.gov ↗ · Healthy Volunteers	Phase 1	Not yet open	2026-04	China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria. NCT06864507 · ClinicalTrials.gov ↗ · Chronic Spontaneous Urticaria	Phase 1/2	Not yet open	2025-03	China
A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese Participants NCT07716241 · ClinicalTrials.gov ↗ · Obesity	Phase 1	Not yet open	2026-09	China
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase NCT05367765 · ClinicalTrials.gov ↗ · CML, Chronic Phase Drug: Imatinib	Phase 4	Not yet open	2022-04	China
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations NCT04687241 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drug: Almonertinib	Phase 3	Active, closed	2021-04	China
Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB NCT06743438 · ClinicalTrials.gov ↗ · Hepatitis B, Chronic Drug: Tenofovir Amibufenamide（TMF）	Phase 4	Active, closed	2022-03	China
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations NCT04923906 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drug: Aumolertinib	Phase 3	Active, closed	2021-08	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Jiangsu Hansoh Pharmaceutical trials

21 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Jiangsu Hansoh Pharmaceutical trials

37 conditions

Non-small Cell Lung Cancer3 Psoriasis2 Type 2 Diabetes2 Non-Small Cell Lung Cancer2 Advanced Solid Tumors2CML, Chronic Phase2Advanced Solid Tumor2IgAN1Immunoglobulin A Nephropathy (IgAN)1Glomerular Disease1Healthy Participants1 Chronic Kidney Disease1Advanced Clear Cell Renal Cell Carcinoma1Hepatitis B, Chronic1Nonsmall Cell Lung Cancer1Ovarian Cancer1 Breast Cancer1 Pancreatic Cancer1Prostatic Cancer1CML, Accelerated Phase1Non Small Cell Lung Cancer1 Colorectal Cancer1Advanced or Metastatic NSCLC1SCHIZOPHRENIA 1 (Disorder)1

By trial register

Register	Trials	Recruiting
Clinical trials in China	32	17
Clinical trials in USA	1	1

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Non-small Cell Lung Cancer

Sponsor	Trials
Sichuan Baili Pharmaceutical	15
AstraZeneca	13
Merck Sharp & Dohme	9
Hoffmann-La Roche	7
Daiichi Sankyo	5
Hunan Province Tumor Hospital	5
Shanghai Pulmonary Hospital, Shanghai, China	4
Shanghai Chest Hospital	4
BioNTech	3
Dizal Pharmaceuticals	3

Sponsors with the most current trials registered for this condition.

Questions about Jiangsu Hansoh Pharmaceutical trials

How many clinical trials does Jiangsu Hansoh Pharmaceutical sponsor?

Jiangsu Hansoh Pharmaceutical is the lead sponsor of 33 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Jiangsu Hansoh Pharmaceutical trials recruiting?

Yes. 18 of its 33 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Jiangsu Hansoh Pharmaceutical testing?

Its current trials name 21 drugs and biologicals as interventions. The most frequent are HS-10370 (3), Adebrelimab (2), Carboplatin (2), HS-10516 (2) and HS-10542 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Jiangsu Hansoh Pharmaceutical clinical trials